NCT01635777View on ClinicalTrials.gov

Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

December 31, 2010

Conditions
PKDL
Interventions
DRUG

Miltefosine

2.5 mg/kg/day for 12 weeks

DRUG

Miltefosine

2.5 mg/kg/day for 8 weeks

Trial Locations (1)

221005

Institute of Medical Sciences, Banaras Hindu University,, Varanasi

All Listed Sponsors
collaborator

World Health Organization

OTHER

lead

AB Foundation

OTHER

NCT01635777 - Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL) | Biotech Hunter | Biotech Hunter